Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Accounts Payables (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Accounts Payables for 16 consecutive years, with $6.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables fell 17.38% to $6.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.9 million, a 17.38% decrease, with the full-year FY2024 number at $7.9 million, up 12.25% from a year prior.
  • Accounts Payables was $6.9 million for Q3 2025 at Xtant Medical Holdings, down from $7.2 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $8.3 million in Q3 2024 to a low of $2.4 million in Q3 2021.
  • A 5-year average of $5.0 million and a median of $4.4 million in 2023 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: crashed 31.01% in 2021, then soared 115.67% in 2024.
  • Xtant Medical Holdings' Accounts Payables stood at $2.6 million in 2021, then surged by 33.46% to $3.5 million in 2022, then skyrocketed by 102.12% to $7.1 million in 2023, then rose by 12.25% to $7.9 million in 2024, then dropped by 13.41% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Accounts Payables are $6.9 million (Q3 2025), $7.2 million (Q2 2025), and $7.1 million (Q1 2025).